1094PClinical prognostic factors in patients (pts) with recurrent and/or metastatic (RM) head and neck carcinoma (HNC) treated with cetuximab plus chemotherapy. (23rd October 2018) - Bossi, P; Depenni, R; cossu rocca, M; Ferrari, D; Azzarello, G; Alù, M; Nolè, F; Codecà, C; Boscolo, G; Piccininni, M; Cavalieri, S; Pugliese, G; et al.